Seema Verma, the nominee to head the Centers for Medicare & Medicaid, said at her confirmation hearing that she would like to review the way pharmaceutical companies classify products as generic or branded, citing the case of Mylan‘s (NSDQ:MYL) EpiPen emergency allergy device.
Mylan faced criticism this year for classifying EpiPen as a generic and paying smaller rebates to Medicaid than if the device was listed as branded.
Get the full story at our sister site, Drug Delivery Business News.